Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 365

1.

Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.

Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M.

Med Care. 2004 Jul;42(7):653-60.

PMID:
15213490
2.

Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.

Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ.

Clin Pharmacol Ther. 2003 Oct;74(4):388-400.

PMID:
14534526
3.

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB.

N Engl J Med. 2002 Mar 14;346(11):822-9.

4.

Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.

Duetz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Soumerai SB.

Clin Ther. 2003 Jan;25(1):273-84.

PMID:
12637126
5.
7.

Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM.

CMAJ. 2002 Mar 19;166(6):737-45.

8.

The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.

Grootendorst PV, Marshall JK, Holbrook AM, Dolovich LR, O'Brien BJ, Levy AR.

Health Serv Res. 2005 Oct;40(5 Pt 1):1297-317.

9.
10.

Prescription duration after drug copay changes in older people: methodological aspects.

Schneeweiss S, Maclure M, Soumerai SB.

J Am Geriatr Soc. 2002 Mar;50(3):521-5.

PMID:
11943050
12.

Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.

Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S.

Ann Intern Med. 2005 Jul 19;143(2):89-99.

PMID:
16027450
13.

Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.

Anderson GM, Kerluke KJ, Pulcins IR, Hertzman C, Barer ML.

Inquiry. 1993 Summer;30(2):199-207.

PMID:
8314608
14.

The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.

Li X, Guh D, Lacaille D, Esdaile J, Anis AH.

Health Policy. 2007 Aug;82(3):340-7. Epub 2006 Nov 28.

PMID:
17134787
15.
16.

Controlling prescription drug expenditures: a report of success.

Miller DP, Furberg CD, Small RH, Millman FM, Ambrosius WT, Harshbarger JS, Ohl CA.

Am J Manag Care. 2007 Aug;13(8):473-80.

17.

The estimated costs and savings of medical nutrition therapy: the Medicare population.

Sheils JF, Rubin R, Stapleton DC.

J Am Diet Assoc. 1999 Apr;99(4):428-35.

PMID:
10207394
18.

Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.

Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR.

CMAJ. 2002 Jun 25;166(13):1655-62.

19.

The effect of incentive-based formularies on prescription-drug utilization and spending.

Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG.

N Engl J Med. 2003 Dec 4;349(23):2224-32.

20.

Supplemental Content

Support Center